[go: up one dir, main page]

HK1175495A1 - New clone of newcastle disease virus, its manufacture and its application in the medical treatment of cancer - Google Patents

New clone of newcastle disease virus, its manufacture and its application in the medical treatment of cancer

Info

Publication number
HK1175495A1
HK1175495A1 HK13102487.1A HK13102487A HK1175495A1 HK 1175495 A1 HK1175495 A1 HK 1175495A1 HK 13102487 A HK13102487 A HK 13102487A HK 1175495 A1 HK1175495 A1 HK 1175495A1
Authority
HK
Hong Kong
Prior art keywords
cancer
manufacture
disease virus
application
newcastle disease
Prior art date
Application number
HK13102487.1A
Other languages
English (en)
Chinese (zh)
Inventor
Christine M Csatary Md
Laszlo K Csatary Md
Original Assignee
United Cancer Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United Cancer Res Inst filed Critical United Cancer Res Inst
Publication of HK1175495A1 publication Critical patent/HK1175495A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
HK13102487.1A 2009-11-30 2013-02-27 New clone of newcastle disease virus, its manufacture and its application in the medical treatment of cancer HK1175495A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28315409P 2009-11-30 2009-11-30
EP09075536A EP2327764B1 (en) 2009-11-30 2009-11-30 New clone of Newcastle disease virus, its manufacture and its application in the medical treatment of cancer
PCT/IB2010/002227 WO2011064630A1 (en) 2009-11-30 2010-08-13 New clone of newcastle disease virus, its manufacture and its application in the medical treatment of cancer

Publications (1)

Publication Number Publication Date
HK1175495A1 true HK1175495A1 (en) 2013-07-05

Family

ID=41581942

Family Applications (1)

Application Number Title Priority Date Filing Date
HK13102487.1A HK1175495A1 (en) 2009-11-30 2013-02-27 New clone of newcastle disease virus, its manufacture and its application in the medical treatment of cancer

Country Status (12)

Country Link
US (2) US8377450B2 (es)
EP (2) EP2327764B1 (es)
JP (1) JP5807788B2 (es)
KR (1) KR20120106741A (es)
CN (1) CN102803477B (es)
AT (1) ATE539148T1 (es)
CA (1) CA2782189C (es)
DK (1) DK2327764T3 (es)
ES (1) ES2380289T3 (es)
HK (1) HK1175495A1 (es)
IL (1) IL207623A (es)
WO (1) WO2011064630A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE539148T1 (de) * 2009-11-30 2012-01-15 United Cancer Res Inst Neuer klon des geflügelpestvirus, herstellung und anwendung bei der medizinischen behandlung von krebs
KR101653401B1 (ko) * 2013-08-28 2016-09-12 주식회사 바이오포아 내열성이 향상된 뉴캣슬병 바이러스 ｂｐ ａｃｎｄ
KR101636683B1 (ko) * 2013-08-28 2016-07-07 주식회사 바이오포아 내열성이 향상된 뉴캣슬병 바이러스 ｂｐ ａｃｎｄｍ
CA2967336C (en) * 2014-11-07 2023-09-26 Case Western Reserve University Cancer immunotherapy using virus particles
RU2644676C1 (ru) * 2016-10-18 2018-02-13 Общество с ограниченной ответственностью "Витагор" (ООО "ВИТАГОР") Штамм вируса болезни Ньюкасла NDVH-2 для изучения возможности разработки на его основе вирусного онколитического препарата
KR101964610B1 (ko) * 2017-03-13 2019-04-03 대한민국 신규한 종양용해성 바이러스 및 이의 용도
EP3552608A1 (en) * 2018-04-09 2019-10-16 Rapo Yerape B.H. Ltd Increased activity of oncoloytic newcastle disease virus
WO2020043835A1 (en) * 2018-08-31 2020-03-05 Thaller, Arno Novel recombinant newcastle disease virus
CN113913553B (zh) * 2021-10-15 2024-08-27 广西壮族自治区兽医研究所 基因ⅻ型新城疫病毒荧光定量rt-pcr检测试剂盒及其引物对

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU197846B (en) 1984-07-02 1989-06-28 Laszlo Csatary Process for producing therapeutic composition suitable for treating virus infections
HU197517B (en) 1984-07-30 1989-04-28 Laszlo Csatary Process for production of terapeutical composition applicable against virus infection
DE3806565A1 (de) 1988-03-01 1989-09-14 Deutsches Krebsforsch Virusmodifizierte tumorvakzinen fuer die immuntherapie von tumormetastasen
US5215745A (en) 1988-04-27 1993-06-01 United Cancer Research Institute Method for treating viral diseases with attenuated virus
US5124148A (en) 1988-04-27 1992-06-23 United Cancer Research Institute Method for treating viral diseases with attenuated virus
HU203983B (en) 1988-12-05 1991-11-28 Mta Allatorvostudomanyi Kutato Process for producing living vaccine against fowlpox
US5602023A (en) 1992-03-24 1997-02-11 Csatary; Laszlo K. Pharmaceutical product containing live, stabilized virus for the therapy of viral and malignant diseases and process for preparing the same
ATE229344T1 (de) 1992-03-24 2002-12-15 United Cancer Res Inst Impfstoff enthaltend lebendes virus
FR2701580B1 (fr) 1993-02-10 1995-03-24 Bull Sa Procédé d'administration d'applications avec des protocoles standards.
DK0696326T5 (da) 1993-04-30 2003-07-14 Wellstat Biologics Corp Anvendelse af NDV til fremstilling af et medikament til behandling af cancer
JPH08116976A (ja) 1994-10-20 1996-05-14 Chemo Sero Therapeut Res Inst 免疫用核酸調製物およびこれを用いた免疫方法
EP0770397B1 (en) 1995-10-18 2004-04-21 Akzo Nobel N.V. Newcastle disease virus combination vaccine
FR2750866B1 (fr) 1996-06-27 1998-11-27 Rhone Merieux Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire
DE69838340T2 (de) 1997-10-09 2008-05-21 Wellstat Biologics Corp. Behandlung von neoplasmen mit interferonempfindlichen, klonalen viren
EP0974660A1 (en) 1998-06-19 2000-01-26 Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) Newcastle disease virus infectious clones, vaccines and diagnostic assays
US6146642A (en) 1998-09-14 2000-11-14 Mount Sinai School Of Medicine, Of The City University Of New York Recombinant new castle disease virus RNA expression systems and vaccines
JP2003530301A (ja) 1999-04-15 2003-10-14 ウェルスタット バイオロジクス コーポレイション ウイルスを用いた新生物の処置
US7244558B1 (en) 1999-05-05 2007-07-17 University Of Maryland Production of novel Newcastle disease virus strains from cDNAs and improved live attenuated Newcastle disease vaccines
WO2000077218A1 (en) 1999-06-10 2000-12-21 Agricultural Research Council Vaccine for newcastle disease virus
CA2412493C (en) 2000-06-26 2010-11-09 Wellstat Biologics Corporation Purging of cells using viruses
AU2001270164A1 (en) 2000-06-26 2002-01-08 The United States Of America As Represented By The Secretary Of Agriculture Production of vaccines using transgenic plants
CA2427578C (en) 2000-11-02 2011-09-06 Akzo Nobel N.V. A recombinant newcastle disease virus nucleoprotein mutant as a marker vaccine
WO2005113013A2 (en) 2004-05-20 2005-12-01 Theravir Management L.P. Compositions of ndv and methods of use thereof for treatment of cancer
IL145397A0 (en) 2001-09-12 2002-06-30 Yissum Res Dev Co Compositions and methods for treatment of cancer
EP2266601A1 (en) 2002-06-21 2010-12-29 Wellstat Biologics Corporation Administration of therapeutic viruses
DE60311665T2 (de) * 2002-08-23 2007-10-25 Schering Corp. Pharmazeutische zusammensetzungen
US20040131595A1 (en) 2002-11-05 2004-07-08 Wellstat Biologics Corporation Treating carcinoid neoplasms with therapeutic viruses
NZ543056A (en) 2003-03-24 2008-04-30 Wellstat Biologics Corp Newcastle disease virus comprising a plurality of doses for treating a mammalian subject having a tumour
JP2006521384A (ja) 2003-03-24 2006-09-21 ウェルスタット バイオロジクス コーポレイション ニューカッスル病ウイルスの投与
WO2005051433A1 (en) 2003-11-25 2005-06-09 United Cancer Research Institute Method for treating human tumor cells with a newcastle disease virus strain and a chemotherapeutic agent
US20060018836A1 (en) 2003-11-25 2006-01-26 United Cancer Research Institute Method for treating human tumor cells with a newcastle disease virus strain having a p53 independent oncolytic effect
CA2562904C (en) 2004-04-27 2013-07-02 Wellstat Biologics Corporation Cancer treatment using viruses and camptothecins
EP2292246A1 (en) 2004-11-12 2011-03-09 Bayer Schering Pharma Aktiengesellschaft Recombinant Newcastle Disease Virus
US7767200B2 (en) 2005-07-14 2010-08-03 Wellstat Biologics Corporation Cancer treatment using viruses, fluoropyrimidines and camptothecins
CN1772886A (zh) 2005-09-02 2006-05-17 中国农业科学院哈尔滨兽医研究所 表达传染性法氏囊病毒VP2基因的重组新城疫LaSota弱毒疫苗株
WO2007064802A1 (en) 2005-12-02 2007-06-07 The Mount Sinai Medical Center Of New York University Chimeric viruses presenting non-native surface proteins and uses thereof
KR100801180B1 (ko) 2006-09-26 2008-02-05 주식회사 고려비엔피 약독화된 재조합 뉴캐슬병 바이러스 및 이를 함유하는뉴캐슬병 백신
WO2008065053A1 (en) 2006-11-27 2008-06-05 Dkfz Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts Multi-modal cancer therapy using viral hitch-hiking
WO2008140621A2 (en) * 2006-12-21 2008-11-20 Mount Sinai School Of Medicine Of New York University Transgenic oncolytic viruses and uses thereof
CN101205544B (zh) * 2007-08-07 2010-12-08 中国人民解放军第四军医大学 肿瘤靶向性重组新城疫病毒及其构建方法
ATE539148T1 (de) * 2009-11-30 2012-01-15 United Cancer Res Inst Neuer klon des geflügelpestvirus, herstellung und anwendung bei der medizinischen behandlung von krebs

Also Published As

Publication number Publication date
US20140030229A1 (en) 2014-01-30
CN102803477B (zh) 2014-12-10
EP2507366A1 (en) 2012-10-10
CA2782189C (en) 2018-07-10
CA2782189A1 (en) 2011-06-03
CN102803477A (zh) 2012-11-28
WO2011064630A8 (en) 2012-05-24
IL207623A (en) 2014-04-30
IL207623A0 (en) 2011-03-31
JP5807788B2 (ja) 2015-11-10
ES2380289T3 (es) 2012-05-10
KR20120106741A (ko) 2012-09-26
JP2013511975A (ja) 2013-04-11
EP2327764A1 (en) 2011-06-01
US20110129446A1 (en) 2011-06-02
US8377450B2 (en) 2013-02-19
EP2327764B1 (en) 2011-12-28
DK2327764T3 (da) 2012-04-02
ATE539148T1 (de) 2012-01-15
WO2011064630A1 (en) 2011-06-03

Similar Documents

Publication Publication Date Title
HK1175495A1 (en) New clone of newcastle disease virus, its manufacture and its application in the medical treatment of cancer
EP1968607A4 (en) TREATMENT OF CANCER AND OTHER DISEASES
SG10201803862UA (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
PL1976886T3 (pl) Środki i metody do leczenia chorób nowotworowych
UA90048C2 (ru) Кондиционированная композиция и способ ее получения
WO2004065423A3 (de) Erkennungsmoleküle zur behandlung und detektion von tumoren
IL201479A (en) Use of tapentadol for the preparation of pain medication
WO2007038459A3 (en) Carboxyamine compounds and their use in the treatment of hdac dependent diseases
EP2046973A4 (en) METHODS OF IDENTIFYING, EVALUATING, AND TREATING PATIENTS SUBJECTED TO ANTICANCER THERAPY
IL216967B (en) The history of 17-hydroxy-17-pentafluoroethyl-astra-9,4 (10)-diene-11-aryl and their use for the treatment of diseases
NZ599928A (en) Use of pentosan polysulfate for treatment or prophylaxis of asthma
EA201001691A1 (ru) Антитела к гранулоцитарно-макрофагальному колониестимулирующему фактору
ATE453642T1 (de) Substituierte phenylaminopyrimidine
MX2009006327A (es) Compuestos heterociclicos y metodos de uso de los mismos.
HK1104460A1 (en) Use for the manufacture of a medicament for treatment or prophylaxis of infectious diseases
RS53911B1 (en) TREATMENT IN HEPATITIS B VIRUS INFECTION ONLY OR IN COMBINATION WITH HEPATITIS DELTA VIRUS AND THE DISEASES OF THE LIVER
TWI372056B (en) Novel medicament combinations for the treatment of respiratory diseases
WO2011075606A3 (en) Hyperglycosylated polypeptide variants and methods of use
WO2007130501A3 (en) Combination therapy for treatment of cancer
WO2007107748A3 (en) Inhibition of tumour growth
IL194353A0 (en) Lysobactin amides
ATE433459T1 (de) Desoxo-nonadepsipeptide
ATE455789T1 (de) Substituierte nonadepsipeptide
DE502005005652D1 (de) Heterocyclyl-substituierte nonadepsipeptide
WO2011075605A3 (en) Hyperglycosylated interferon variants and methods of use

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20230809